NextCure, Inc. (NXTC)

NextCure Statistics

Total Valuation

NextCure has a market cap or net worth of $44.45 million. The enterprise value is $21.15 million.

Market Cap	44.45M
Enterprise Value	21.15M

Important Dates

The next estimated earnings date is Thursday, March 5, 2026, after market close.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

NextCure has 3.51 million shares outstanding. The number of shares has increased by 4.40% in one year.

Current Share Class	3.51M
Shares Outstanding	3.51M
Shares Change (YoY)	+4.40%
Shares Change (QoQ)	+12.69%
Owned by Insiders (%)	1.26%
Owned by Institutions (%)	17.97%
Float	2.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.47
P/TBV Ratio	1.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.23.

Current Ratio	2.97
Quick Ratio	2.67
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -116.91% and return on invested capital (ROIC) is -68.08%.

Return on Equity (ROE)	-116.91%
Return on Assets (ROA)	-58.01%
Return on Invested Capital (ROIC)	-68.08%
Return on Capital Employed (ROCE)	-210.76%
Revenue Per Employee	n/a
Profits Per Employee	-$1.35M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +30.83% in the last 52 weeks. The beta is 1.53, so NextCure's price volatility has been higher than the market average.

Beta (5Y)	1.53
52-Week Price Change	+30.83%
50-Day Moving Average	12.05
200-Day Moving Average	7.48
Relative Strength Index (RSI)	49.11
Average Volume (20 Days)	31,484

Short Selling Information

The latest short interest is 32,483, so 0.93% of the outstanding shares have been sold short.

Short Interest	32,483
Short Previous Month	26,706
Short % of Shares Out	0.93%
Short % of Float	1.20%
Short Ratio (days to cover)	0.84

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-60.31M
Pretax Income	-58.01M
Net Income	-58.01M
EBITDA	-57.82M
EBIT	-60.31M
Earnings Per Share (EPS)	-$23.87

Balance Sheet

The company has $29.11 million in cash and $5.39 million in debt, with a net cash position of $23.72 million or $6.77 per share.

Cash & Cash Equivalents	29.11M
Total Debt	5.39M
Net Cash	23.72M
Net Cash Per Share	$6.77
Equity (Book Value)	23.65M
Book Value Per Share	8.84
Working Capital	21.65M

Cash Flow

In the last 12 months, operating cash flow was -$48.94 million and capital expenditures $34,000, giving a free cash flow of -$48.91 million.

Operating Cash Flow	-48.94M
Capital Expenditures	34,000
Free Cash Flow	-48.91M
FCF Per Share	-$13.95

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NextCure does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.40%
Shareholder Yield	-4.40%
Earnings Yield	-129.28%
FCF Yield	-109.00%

Analyst Forecast

The average price target for NextCure is $23.00, which is 81.39% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$23.00
Price Target Difference	81.39%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-54.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:12.

Last Split Date	Jul 14, 2025
Split Type	Reverse
Split Ratio	1:12

Scores

Altman Z-Score	n/a
Piotroski F-Score	1